1. histological confirmed PCa or suspicion of PCa (abnormal PSA values and/or positive DRE);
2. magnetic resonance imaging examination, including at least a high-resolution axial T2-weighted imaging and axila diffusion-weighted imaging (dynamic contrast-enhanced imaging is recommended, but not mandatory);
3. age ≥ 18 years at the time of diagnosis
4. signed written informed consent form (only for prospective enrollement).
Clareo Health | An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum
